BioXcel Therapeutics (BTAI) Should Benefit from Alzheimer's Approval - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $128.00 price target on BioXcel Therapeutics (NASDAQ: BTAI), saying it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
